ClinicalTrials.govpublic full text
Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
bile duct cancer, durvalumab + chemotherapy, radiofrequency ablation, adverse events, chemo-immune-checkpoint-inhibitor, extra hepatic biliary tract cancer, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 843388
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.